{"id":"f880c486-faa4-5915-8512-d99b9336225d","stable_key":"c836a883-ac18-5eb2-9971-2f0b542feba8:scope-aged-garlic-nantz-2012","predicate":"has_distinct_clinical_preparation_comparison","statement":"The aged-garlic-nantz-2012 study is a preparation-specific translation comparison; its outcomes are not assigned to purified allicin. ","claim_class":"identity","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"d932042e-6e55-563c-8d00-a714728a8aec","mechanism_event_label":"The aged-garlic-nantz-2012 study is a preparation-specific translation comparison; its outcomes are not assigned to purified allicin. ","subject":{"id":"85c86fcf-3060-5fae-b567-4f089990ab2d","slug":"allicin","display_name":"Allicin","entity_type_key":"small_molecule"},"object":{"id":"835615f7-1a22-5169-b091-f7cf95f9e9c5","slug":"aged-garlic-nantz-2012","display_name":"Aged garlic extract in Nantz 2012","entity_type_key":"botanical"},"evidence_count":1,"mechanism_event":{"id":"d932042e-6e55-563c-8d00-a714728a8aec","stable_key":"c836a883-ac18-5eb2-9971-2f0b542feba8:scope-aged-garlic-nantz-2012-event","event_type":"experimental_scope_comparison","label":"The aged-garlic-nantz-2012 study is a preparation-specific translation comparison; its outcomes are not assigned to purified allicin. ","description":"**Cold outcomes differ by preparation.** Josling's trial randomized 146 volunteers for twelve weeks and reported fewer diary-recorded colds with an allicin-containing supplement (24 versus 65 episodes). Nantz tested 2.56 g/day aged garlic extract in 120 participants: the ninety-day cold/flu incidence difference was not significant, although some symptom and activity-impact measures improved. At forty-five days, ex vivo γδ-T-cell and NK-cell proliferation also increased. These are different interventions and endpoints, not a replication of purified allicin efficacy. Neither proves that one specific compound caused the clinical effect. [Josling 2001](https://pubmed.ncbi.nlm.nih.gov/11697022/) [Nantz 2012](https://pubmed.ncbi.nlm.nih.gov/22280901/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"85c86fcf-3060-5fae-b567-4f089990ab2d","slug":"allicin","display_name":"Allicin","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"835615f7-1a22-5169-b091-f7cf95f9e9c5","slug":"aged-garlic-nantz-2012","display_name":"Aged garlic extract in Nantz 2012","entity_type_key":"botanical"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary indexed abstract reviewed; full methods, exact concentrations or species-specific attribution remain unextracted unless explicitly stated in the abstract or separately verified publisher text.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Editorial study-scope relationship, not experimental causation or chemical composition.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Unsigned navigation only. Does not assert allicin content, metabolic conversion, causation or intervention equivalence.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The aged-garlic-nantz-2012 study is a preparation-specific translation comparison; its outcomes are not assigned to purified allicin. ","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Supplementation with aged garlic extract improves both NK and γδ-T cell function and reduces the severity of cold and flu symptoms: a randomized, double-blind, placebo-controlled nutrition intervention. | 2012 | DOI 10.1016/j.clnu.2011.11.019 | PMID 22280901 | https://pubmed.ncbi.nlm.nih.gov/22280901/ | https://doi.org/10.1016/j.clnu.2011.11.019","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 95-95; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"70d259db-d2e0-5a85-aaca-70b5b544bdc3","evidence_kind":"source_excerpt","locator":"Lines 95-95","start_line":95,"end_line":95,"excerpt":"**Cold outcomes differ by preparation.** Josling's trial randomized 146 volunteers for twelve weeks and reported fewer diary-recorded colds with an allicin-containing supplement (24 versus 65 episodes). Nantz tested 2.56 g/day aged garlic extract in 120 participants: the ninety-day cold/flu incidence difference was not significant, although some symptom and activity-impact measures improved. At forty-five days, ex vivo γδ-T-cell and NK-cell proliferation also increased. These are different interventions and endpoints, not a replication of purified allicin efficacy. Neither proves that one specific compound caused the clinical effect. [Josling 2001](https://pubmed.ncbi.nlm.nih.gov/11697022/) [Nantz 2012](https://pubmed.ncbi.nlm.nih.gov/22280901/)","model_system":"Editorial study-scope relationship, not experimental causation or chemical composition.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"10820a6b-594a-547d-97f9-906ab4cc1d6e","stable_key":"import-c836a883-ac18-5eb2-9971-2f0b542feba8","title":"Allicin: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"2475d3eb681100a0a34577a47b7cba5b251df866fbd6ce795122ccabee360018","revision_id":"590df96d-2ed1-5763-b04c-bf0e096e603c","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}